Receptor-activating autoantibodies and disease: preeclampsia and beyond

References

• Davies TF, Ando T, Lin RY, Tomer Y, Latif R. Thyrotropin receptor-associated diseases: from adenomata to Graves disease. J. Clin. Invest.115(8), 1972–1983 (2005).
   PubMed Web of Science ®Google Scholar
• Michalek K, Morshed SA, Latif R, Davies TF. TSH receptor autoantibodies. Autoimmun. Rev.9(2), 113–116 (2009).
   PubMed Web of Science ®Google Scholar
• Jacobson DL, Gange SJ, Rose NR, Graham NM. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin. Immunol. Immunopathol.84(3), 223–243 (1997).
   PubMedGoogle Scholar
• Adams DD, Fastier FN, Howie JB, Kennedy TH, Kilpatrick JA, Stewart RD. Stimulation of the human thyroid by infusions of plasma containing LATS protector. J. Clin. Endocrinol. Metab.39(5), 826–832 (1974).
   PubMedGoogle Scholar
• Costagliola S, Rodien P, Many MC, Ludgate M, Vassart G. Genetic immunization against the human thyrotropin receptor causes thyroiditis and allows production of monoclonal antibodies recognizing the native receptor. J. Immunol.160(3), 1458–1465 (1998).
   PubMed Web of Science ®Google Scholar
• Laurberg P, Bournaud C, Karmisholt J, Orgiazzi J. Management of Graves’ hyperthyroidism in pregnancy: focus on both maternal and foetal thyroid function, and caution against surgical thyroidectomy in pregnancy. Eur. J. Endocrinol./Eur. Federat. Endocrine Soc.160(1), 1–8 (2009).
   PubMed Web of Science ®Google Scholar
• Smith BR, Hall R. Thyroid-stimulating immunoglobulins in Graves’ disease. Lancet2(7878), 427–431 (1974).
   PubMed Web of Science ®Google Scholar
• Ajjan RA, Weetman AP. Techniques to quantify TSH receptor antibodies. Nat. Clin. Pract. Endocrinol. Metab.4(8), 461–468 (2008).
   PubMedGoogle Scholar
• Sanders J, Evans M, Premawardhana LD et al. Human monoclonal thyroid stimulating autoantibody. Lancet362(9378), 126–128 (2003).
   PubMedGoogle Scholar
• Smith BR, Bolton J, Young S et al. A new assay for thyrotropin receptor autoantibodies. Thyroid14(10), 830–835 (2004).
   PubMedGoogle Scholar
• Nakatake N, Sanders J, Richards T et al. Estimation of serum TSH receptor autoantibody concentration and affinity. Thyroid16(11), 1077–1084 (2006).
   PubMedGoogle Scholar
• El Fassi D, Banga JP, Gilbert JA, Padoa C, Hegedus L, Nielsen CH. Treatment of Graves’ disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin. Immunol.130(3), 252–258 (2009).
   PubMed Web of Science ®Google Scholar
• Sanders J, Jeffreys J, Depraetere H et al. Characteristics of a human monoclonal autoantibody to the thyrotropin receptor: sequence structure and function. Thyroid14(8), 560–570 (2004).
   PubMedGoogle Scholar
• Smith BR, Sanders J, Furmaniak J. TSH receptor antibodies. Thyroid17(10), 923–938 (2007).
   PubMed Web of Science ®Google Scholar
• Sanders J, Chirgadze DY, Sanders P et al. Crystal structure of the TSH receptor in complex with a thyroid-stimulating autoantibody. Thyroid17(5), 395–410 (2007).
   PubMed Web of Science ®Google Scholar
• Costagliola S, Many MC, Denef JF, Pohlenz J, Refetoff S, Vassart G. Genetic immunization of outbred mice with thyrotropin receptor cDNA provides a model of Graves’ disease. J. Clin. Invest.105(6), 803–811 (2000).
   PubMed Web of Science ®Google Scholar
• Nagayama Y, Kita-Furuyama M, Ando T et al. A novel murine model of Graves’ hyperthyroidism with intramuscular injection of adenovirus expressing the thyrotropin receptor. J. Immunol.168(6), 2789–2794 (2002).
   PubMed Web of Science ®Google Scholar
• Borda E, Pascual J, Cossio P, De La Vega M, Arana R, Sterin-Borda L. A circulating IgG in Chagas’ disease which binds to β-adrenoceptors of myocardium and modulates their activity. Clin. Exp. Immunol.57(3), 679–686 (1984).
   PubMedGoogle Scholar
• Jahns R, Boivin V, Lohse MJ. β(1)-Adrenergic receptor function, autoimmunity, and pathogenesis of dilated cardiomyopathy. Trends Cardiovasc. Med.16(1), 20–24 (2006).
   PubMed Web of Science ®Google Scholar
• Limas CJ, Goldenberg IF, Limas C. Autoantibodies against β-adrenoceptors in human idiopathic dilated cardiomyopathy. Circ. Res.64(1), 97–103 (1989).
   PubMed Web of Science ®Google Scholar
• Magnusson Y, Marullo S, Hoyer S et al. Mapping of a functional autoimmune epitope on the β 1-adrenergic receptor in patients with idiopathic dilated cardiomyopathy. J. Clin. Invest.86(5), 1658–1663 (1990).
   PubMed Web of Science ®Google Scholar
• Wallukat G, Morwinski M, Kowal K, Forster A, Boewer V, Wollenberger A. Autoantibodies against the β-adrenergic receptor in human myocarditis and dilated cardiomyopathy: β-adrenergic agonism without desensitization. Eur. Heart. J.12(Suppl. D), 178–181 (1991).
   PubMed Web of Science ®Google Scholar
• Magnusson Y, Wallukat G, Waagstein F, Hjalmarson A, Hoebeke J. Autoimmunity in idiopathic dilated cardiomyopathy. Characterization of antibodies against the β 1-adrenoceptor with positive chronotropic effect. Circulation89(6), 2760–2767 (1994).
   PubMed Web of Science ®Google Scholar
• Magnusson Y, Hjalmarson A, Hoebeke J. β 1-adrenoceptor autoimmunity in cardiomyopathy. Int. J. Cardiol.54(2), 137–141 (1996).
   PubMed Web of Science ®Google Scholar
• Mobini R, Fu M, Wallukat G, Magnusson Y, Hjalmarson A, Hoebeke J. A monoclonal antibody directed against an autoimmune epitope on the human β 1-adrenergic receptor recognized in idiopathic dilated cardiomyopathy. Hybridoma19(2), 135–142 (2000).
   PubMedGoogle Scholar
• Nikolaev VO, Boivin V, Stork S et al. A novel fluorescence method for the rapid detection of functional β 1-adrenergic receptor autoantibodies in heart failure. J. Am. Coll. Cardiol.50(5), 423–431 (2007).
   PubMed Web of Science ®Google Scholar
• Wallukat G, Nissen E, Morwinski R, Muller J. Autoantibodies against the β- and muscarinic receptors in cardiomyopathy. Herz25(3), 261–266 (2000).
   PubMed Web of Science ®Google Scholar
• Munoz-Saravia SG, Haberland A, Wallukat G, Schimke I. Chronic Chagas’ heart disease: a disease on its way to becoming a worldwide health problem: epidemiology, etiopathology, treatment, pathogenesis and laboratory medicine. Heart Fail. Rev. DOI: 10.1007/s10741-010-9211-5 (2010) (Epub ahead of print).
   Google Scholar
• Wallukat G, Munoz Saravia SG, Haberland A et al. Distinct patterns of autoantibodies against G-protein-coupled receptors in Chagas’ cardiomyopathy and megacolon. Their potential impact for early risk assessment in asymptomatic Chagas’ patients. J. Am. Coll. Cardiol.55(5), 463–468 (2010).
   PubMed Web of Science ®Google Scholar
• Jahns R, Boivin V, Schwarzbach V, Ertl G, Lohse MJ. Pathological autoantibodies in cardiomyopathy. Autoimmunity41(6), 454–461 (2008).
   PubMed Web of Science ®Google Scholar
• Ferrari I, Levin MJ, Wallukat G et al. Molecular mimicry between the immunodominant ribosomal protein P0 of Trypanosoma cruzi and a functional epitope on the human β 1-adrenergic receptor. J. Exp. Med.182(1), 59–65 (1995).
   PubMed Web of Science ®Google Scholar
• Wallukat G, Wollenberger A. Effects of the serum γ globulin fraction of patients with allergic asthma and dilated cardiomyopathy on chronotropic β adrenoceptor function in cultured neonatal rat heart myocytes. Biomedica Biochimica Acta46(8–9), S634–S639 (1987).
   Google Scholar
• Jahns R, Boivin V, Hein L et al. Direct evidence for a β 1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J. Clin. Invest.113(10), 1419–1429 (2004).
   PubMed Web of Science ®Google Scholar
• Jahns R, Boivin V, Lohse MJ. β 1-adrenergic receptor-directed autoimmunity as a cause of dilated cardiomyopathy in rats. Int. J. Cardiol.112(1), 7–14 (2006).
   PubMed Web of Science ®Google Scholar
• Christ T, Wettwer E, Dobrev D et al. Autoantibodies against the β 1 adrenoceptor from patients with dilated cardiomyopathy prolong action potential duration and enhance contractility in isolated cardiomyocytes. J. Mol. Cell. Cardiol.33(8), 1515–1525 (2001).
   PubMedGoogle Scholar
• Deubner N, Berliner D, Schlipp A et al. Cardiac β 1-adrenoceptor autoantibodies in human heart disease: rationale and design of the Etiology, Titre-Course, and Survival (ETiCS) Study. Eur. J. Heart Fail.12(7), 753–762 (2010).
   PubMed Web of Science ®Google Scholar
• Fu ML, Herlitz H, Wallukat G et al. Functional autoimmune epitope on α 1-adrenergic receptors in patients with malignant hypertension. Lancet344(8938), 1660–1663 (1994).
   PubMed Web of Science ®Google Scholar
• Luther HP, Homuth V, Wallukat G. α 1-adrenergic receptor antibodies in patients with primary hypertension. Hypertension29(2), 678–682 (1997).
   PubMed Web of Science ®Google Scholar
• Wenzel K, Haase H, Wallukat G et al. Potential relevance of α(1)-adrenergic receptor autoantibodies in refractory hypertension. PLoS ONE3(11), e3742 (2008).
   PubMed Web of Science ®Google Scholar
• Yan L, Xu Y, Yao H et al. The effects of autoantibodies against the second extracellular loop of α(1)-adrenoceptor on vasoconstriction. Basic Res. Cardiol.104(5), 581–589 (2009).
   PubMed Web of Science ®Google Scholar
• Wenzel K, Wallukat G, Qadri F et al. α 1A-adrenergic receptor-directed autoimmunity induces left ventricular damage and diastolic dysfunction in rats. PLoS ONE5(2), e9409 (2010).
   Google Scholar
• Karczewski P, Haase H, Hempel P, Bimmler M. Agonistic antibody to the α 1-adrenergic receptor mobilizes intracellular calcium and induces phosphorylation of a cardiac 15-kDa protein. Mol. Cell. Biochem.333(1–2), 233–242 (2009).
   PubMedGoogle Scholar
• Young BC, Levine RJ, Karumanchi SA. Pathogenesis of preeclampsia. Ann. Rev. Pathol.5, 173–192 (2010).
   PubMed Web of Science ®Google Scholar
• Roberts JM, Cooper DW. Pathogenesis and genetics of pre-eclampsia. Lancet357, 53–56 (2001).
   PubMed Web of Science ®Google Scholar
• Xia Y, Zhou CC, Ramin SM, Kellems RE. Angiotensin receptors, autoimmunity, and preeclampsia. J. Immunol.179(6), 3391–3395 (2007).
   PubMed Web of Science ®Google Scholar
• Lamarca BD, Gilbert J, Granger JP. Recent progress toward the understanding of the pathophysiology of hypertension during preeclampsia. Hypertension51(4), 982–988 (2008).
   PubMed Web of Science ®Google Scholar
• Xia Y, Kellems RE. Is preeclampsia an autoimmune disease? Clin. Immunol.133(1), 1–12 (2009).
   PubMedGoogle Scholar
• Wenzel K, Rajakumar A, Haase H et al. Angiotensin II type 1 receptor antibodies and increased angiotensin II sensitivity in pregnant rats. Hypertension58(1), 77–84 (2011).
   PubMed Web of Science ®Google Scholar
• Herse F, Verlohren S, Wenzel K et al. Prevalence of agonistic autoantibodies against the angiotensin II type 1 receptor and soluble fms-like tyrosine kinase 1 in a gestational age-matched case study. Hypertension53(2), 393–398 (2009).
   PubMed Web of Science ®Google Scholar
• Wallukat G, Homuth V, Fischer T et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J. Clin. Invest.103(7), 945–952 (1999).
   PubMed Web of Science ®Google Scholar
• Dechend R, Viedt C, Muller DN et al. AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation107(12), 1632–1639 (2003).
   PubMed Web of Science ®Google Scholar
• Dechend R, Homuth V, Wallukat G et al. AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor. Circulation101(20), 2382–2387 (2000).
   PubMed Web of Science ®Google Scholar
• Bobst SM, Day MC, Gilstrap LC 3rd, Xia Y, Kellems RE. Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human mesangial cells and induce interleukin-6 and plasminogen activator inhibitor-1 secretion. Am. J. Hypertens.18(3), 330–336 (2005).
   PubMed Web of Science ®Google Scholar
• Xia Y, Wen H, Bobst S, Day MC, Kellems RE. Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells. J. Soc. Gynecol. Invest.10(2), 82–93 (2003).
   PubMedGoogle Scholar
• Zhou CC, Ahmad S, Mi T et al. Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling. Hypertension51(4), 1010–1019 (2008).
   PubMed Web of Science ®Google Scholar
• Zhou CC, Irani RA, Zhang Y et al. Angiotensin receptor agonistic autoantibody-mediated tumor necrosis factor-α induction contributes to increased soluble endoglin production in preeclampsia. Circulation121(3), 436–444 (2010).
   PubMed Web of Science ®Google Scholar
• Yang X, Wang F, Chang H et al. Autoantibody against AT1 receptor from preeclamptic patients induces vasoconstriction through angiotensin receptor activation. J. Hypertens.26(8), 1629–1635 (2008).
   PubMed Web of Science ®Google Scholar
• Zhou CC, Zhang Y, Irani RA et al. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat. Med.14(8), 855–862 (2008).
   PubMed Web of Science ®Google Scholar
• Siddiqui AH, Irani RA, Blackwell SC, Ramin SM, Kellems RE, Xia Y. Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: correlation with disease severity. Hypertension55(2), 386–393 (2010).
   PubMed Web of Science ®Google Scholar
• Kaufmann P, Black S, Huppertz B. Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia. Biol. Reproduct.69(1), 1–7 (2003).
   PubMed Web of Science ®Google Scholar
• Barker DJ. In utero programming of chronic disease. Clin. Sci. (Lond.)95(2), 115–128 (1998).
   PubMed Web of Science ®Google Scholar
• Godfrey KM, Barker DJ. Fetal nutrition and adult disease. Am. J. Clin. Nutrit.71(Suppl. 5), S1344–S1352 (2000).
   PubMed Web of Science ®Google Scholar
• Baum M, Ortiz L, Quan A. Fetal origins of cardiovascular disease. Curr. Opin. Pediat.15(2), 166–170 (2003).
   PubMedGoogle Scholar
• Irani RA, Zhang Y, Blackwell SC et al. The detrimental role of angiotensin receptor agonistic autoantibodies in intrauterine growth restriction seen in preeclampsia. J. Exp. Med.206(12), 2809–2822 (2009).
   PubMed Web of Science ®Google Scholar
• Gadonski G, Lamarca BB, Sullivan E, Bennett W, Chandler D, Granger JP. Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of interleukin 6. Hypertension48(4), 711–716 (2006).
   PubMed Web of Science ®Google Scholar
• Gilbert JS, Ryan MJ, Lamarca BB, Sedeek M, Murphy SR, Granger JP. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am. J. Physiol. Heart Circ. Physiol.294(2), H541–H550 (2008).
   PubMed Web of Science ®Google Scholar
• Parrish MR, Murphy SR, Rutland S et al. The effect of immune factors, tumor necrosis factor-α, and agonistic autoantibodies to the angiotensin II type I receptor on soluble fms-like tyrosine-1 and soluble endoglin production in response to hypertension during pregnancy. Am. J. Hypertens.23(8), 911–916 (2010).
   PubMed Web of Science ®Google Scholar
• Li Z, Zhang Y, Ying Ma J et al. Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension50(4), 686–692 (2007).
   PubMed Web of Science ®Google Scholar
• LaMarca B, Wallukat G, Llinas M, Herse F, Dechend R, Granger JP. Autoantibodies to the angiotensin type I receptor in response to placental ischemia and tumor necrosis factor α in pregnant rats. Hypertension52(6), 1168–1172 (2008).
   PubMed Web of Science ®Google Scholar
• Lamarca B, Parrish M, Ray LF et al. Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1. Hypertension54(4), 905–909 (2009).
   PubMed Web of Science ®Google Scholar
• Lamarca B, Wallace K, Herse F et al. Hypertension in response to placental ischemia during pregnancy: role of B lymphocytes. Hypertension57(4), 865–871 (2011).
   PubMed Web of Science ®Google Scholar
• Wallace K, Richards S, Dhillon P et al. CD4+ T-helper cells stimulated in response to placental ischemia mediate hypertension during pregnancy. Hypertension57(5), 949–955 (2011).
   PubMed Web of Science ®Google Scholar
• Dechend R, Gratze P, Wallukat G et al. Agonistic autoantibodies to the AT1 receptor in a transgenic rat model of preeclampsia. Hypertension45(4), 742–746 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang SL, Du YH, Wang J et al. Endothelial dysfunction induced by antibodies against angiotensin AT1 receptor in immunized rats. Acta Pharmacol. Sin.31(10), 1381–1388 (2010).
   PubMedGoogle Scholar
• Irani RA, Zhang Y, Zhou CC et al. Autoantibody-mediated angiotensin receptor activation contributes to preeclampsia through tumor necrosis factor-α signaling. Hypertension55(5), 1246–1253 (2010).
   PubMed Web of Science ®Google Scholar
• Zhou CC, Irani RA, Dai Y et al. Autoantibody-mediated IL-6-dependent endothelin-1 elevation underlies pathogenesis in a mouse model of preeclampsia. J. Immunol.186(10), 6024–6034 (2011).
   PubMed Web of Science ®Google Scholar
• Zhou CC, Irani RA, Zhang Y et al. Angiotensin receptor agonistic autoantibody-mediated tumor necrosis factor-α induction contributes to increased soluble endoglin production in preeclampsia. Circulation121(3), 436–444 (2010).
   PubMed Web of Science ®Google Scholar
• Parrish MR, Wallace K, Tam Tam KB et al. Hypertension in response to AT1-AA: Role of reactive oxygen species in pregnancy-induced hypertension. Am. J. Hypertens.24(7), 835–840 (2011).
   PubMed Web of Science ®Google Scholar
• Parrish MR, Ryan MJ, Glover P et al. Angiotensin II type 1 autoantibody induced hypertension during pregnancy is associated with renal endothelial dysfunction. Gender Med.8(3), 184–188.
   PubMedGoogle Scholar
• LaMarca B, Wallace K, Granger J. Role of angiotensin II type I receptor agonistic autoantibodies (AT1-AA) in preeclampsia. Curr. Opin. Pharmacol.11(2), 175–179 (2011).
   PubMed Web of Science ®Google Scholar
• Dragun D, Brasen JH, Schonemann C et al. Patients with steroid refractory acute vascular rejection develop agonistic antibodies targeting angiotensin II type 1 receptor. Transplant. Proc.35(6), 2104–2105 (2003).
   PubMedGoogle Scholar
• Dragun D, Muller DN, Brasen JH et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N. Engl. J. Med.352(6), 558–569 (2005).
   PubMed Web of Science ®Google Scholar
• Dragun D. Agonistic antibody-triggered stimulation of Angiotensin II type 1 receptor and renal allograft vascular pathology. Nephrol. Dial. Transplant.22(7), 1819–1822 (2007).
   PubMed Web of Science ®Google Scholar
• Fu ML, Herlitz H, Schulze W et al. Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension. J. Hypertens.18(7), 945–953 (2000).
   PubMed Web of Science ®Google Scholar
• Wei F, Jia XJ, Yu SQ et al. Candesartan versus imidapril in hypertension: a randomised study to assess effects of anti-AT1 receptor autoantibodies. Heart97(6), 479–484 (2011).
   PubMedGoogle Scholar
• Sun YX, Zhang HY, Wei YM, Zhu F, Wang M, Liao YH. The mechanism of signal transduction during vascular smooth muscle cell proliferation induced by autoantibodies against angiotensin AT1 receptor from hypertension. Chinese Med. J.121(1), 43–48 (2008).
   PubMedGoogle Scholar
• Liao YH, Wei YM, Wang M, Wang ZH, Yuan HT, Cheng LX. Autoantibodies against AT1-receptor and α1-adrenergic receptor in patients with hypertension. Hypertens. Res.25(4), 641–646 (2002).
   PubMed Web of Science ®Google Scholar
• Dragun D. The role of angiotensin II type 1 receptor-activating antibodies in renal allograft vascular rejection. Pediat. Nephrol. (Berlin, Germany)22(7), 911–914 (2007).
   PubMedGoogle Scholar
• Reinsmoen NL, Lai CH, Heidecke H et al. Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation90(12), 1473–1477 (2010).
   PubMed Web of Science ®Google Scholar
• Riemekasten G, Philippe A, Nather M et al. Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann. Rheum. Dis.70(3), 530–536 (2010).
   PubMed Web of Science ®Google Scholar
• Walllukat GDM, Muller J, Bartel S, Schulze W, Hetzer R. Agonistic autoantibodies against the endothelin 1 ETA- and α 1-adrenergic receptor in the sera of patients with idiopathic pulmonary arterial hypertension. Circulation116(II), 503 (2007).
   Google Scholar
• Dandel MWG, Englert A, Lehmkul HB, Hetzer R. Potential pathogenetic involvement of agonistic autoantibodies against α-1 adrenergic and endothelin-1 receptors in pulmonary arterial hypertension. Circulation118, S1072 (2008).
   Google Scholar
• Dandel MWG, Englert A, Lehmkul HB, Hetzer R. Agonistic autoantibodies against α-1 adrenergic and endothelin-1 receptors in sera of patients with pulmonary arterial hypertension: potential involvement in the pathogenesis of the disease. J. Heart Lung Transplant.28(2), S249 (2009).
   PubMedGoogle Scholar
• Dragun D, Philippe A, Catar R, Hegner B. Autoimmune mediated G-protein receptor activation in cardiovascular and renal pathologies. Thrombo. Haemost.101(4), 643–648 (2009).
   PubMedGoogle Scholar
• Walther T, Wallukat G, Jank A et al. Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculature. Hypertension46(6), 1275–1279 (2005).
   PubMed Web of Science ®Google Scholar
• Chen CR, Pichurin P, Nagayama Y, Latrofa F, Rapoport B, Mclachlan SM. The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim. J. Clin. Invest.111(12), 1897–1904 (2003).
   PubMed Web of Science ®Google Scholar
• Mizutori Y, Chen CR, Latrofa F, Mclachlan SM, Rapoport B. Evidence that shed thyrotropin receptor A subunits drive affinity maturation of autoantibodies causing Graves’ disease. J. Clin. Endocrinol. Metab.94(3), 927–935 (2009).
   PubMed Web of Science ®Google Scholar
• Gigler A, Dorsch S, Hemauer A et al. Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins. J. Virol.73(3), 1974–1979 (1999).
   PubMed Web of Science ®Google Scholar
• Stepan H, Wallukat G, Schultheiss HP, Faber R, Walther T. Is parvovirus B19 the cause for autoimmunity against the angiotensin II type receptor? J. Reprod. Immunol.73(2), 130–134 (2007).
   PubMed Web of Science ®Google Scholar
• Bai M. Dimerization of G-protein-coupled receptors: roles in signal transduction. Cell. Signalling16(2), 175–186 (2004).
   PubMed Web of Science ®Google Scholar
• Breitwieser GE. G protein-coupled receptor oligomerization: implications for G protein activation and cell signaling. Cir. Res.94(1), 17–27 (2004).
   PubMedGoogle Scholar
• Terrillon S, Bouvier M. Roles of G-protein-coupled receptor dimerization. EMBO Reports5(1), 30–34 (2004).
   PubMed Web of Science ®Google Scholar
• Abdalla S, Lother H, Quitterer U. AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature407(6800), 94–98 (2000).
   PubMed Web of Science ®Google Scholar
• Abdalla S, Lother H, El Massiery A, Quitterer U. Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat. Med.7(9), 1003–1009 (2001).
   PubMed Web of Science ®Google Scholar
• Szkudlinski MW, Fremont V, Ronin C, Weintraub BD. Thyroid-stimulating hormone and thyroid-stimulating hormone receptor structure-function relationships. Physiol. Rev.82(2), 473–502 (2002).
   PubMed Web of Science ®Google Scholar